Solid Tumor Clinical Trials

A listing of Solid Tumor medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 907 clinical trials
Efficacy and Safety Study of Tisotumab Vedotin for Patients With Solid Tumors (innovaTV 207)

This trial will study tisotumab vedotin to find out whether it is an effective treatment for certain solid tumors and what side effects (unwanted effects) may occur. There are four parts to this

fluoropyrimidine
systemic therapy
gemcitabine
adenocarcinoma
pembrolizumab
  • 247 views
  • 07 Oct, 2022
  • 33 locations
GEN1042 Safety Trial and Anti-tumor Activity in Subjects With Malignant Solid Tumors

To evaluate the safety and anti-tumor activity of GEN1042 in patients with metastatic or locally advanced solid tumors

5-fluorouracil
systemic therapy
gemcitabine
metastatic melanoma
pembrolizumab
  • 30 views
  • 04 Oct, 2022
  • 16 locations
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099318 in Participants With Advanced Solid Tumors

The purpose of this study is to evaluate the safety and tolerability, pharmacokinetics, and pharmacodynamics of INCB099318 in select solid tumors.

  • 0 views
  • 04 Oct, 2022
  • 23 locations
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099318 in Participants With Advanced Solid Tumors

The purpose of this study is to evaluate the safety and tolerability, pharmacokinetics, and pharmacodynamics of INCB099318 in select solid tumors.

  • 1 views
  • 04 Oct, 2022
  • 23 locations
Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)

To evaluate the safety and tolerability of sotorasib administered in investigational regimens in adult participants with KRAS p.G12C mutant advanced solid tumors.

  • 26 views
  • 07 Oct, 2022
  • 74 locations
Study of the Safety and Effectiveness of GSK6097608 in Participants With Advanced Solid Tumors

given as monotherapy and in combination with dostarlimab in participants with advanced solid tumors. In addition, dostarlimab will be given as monotherapy and in combination with GSK6097608 and with

solid neoplasm
measurable disease
primary cancer
  • 35 views
  • 07 Oct, 2022
  • 9 locations
Tusamitamab Ravtansine Monotherapy and in Combination in Patients With CEACAM5-positive Advanced Solid Tumors (CARMEN-BT01)

Primary Objective: For Cohort A, Cohort B, and Cohort C Part 2: To assess the antitumor activity of tusamitamab ravtansine in metastatic breast cancer (mBC) and tusamitamab ravtansine monotherapy and in combination with gemcitabine in metastatic pancreatic adenocarcinoma (mPAC) For Cohort C Part 1: Confirmation of the recommended tusamitamab ravtansine …

  • 0 views
  • 13 Jan, 2023
  • 23 locations
A Phase 1/2 Study of Oral Selpercatinib (LOXO-292) in Patients With Advanced Solid Tumors, Including RET Fusion-Positive Solid Tumors, Medullary Thyroid Cancer, and Other Tumors With RET Activation (LIBRETTO-001) (LIBRETTO-001)

) administered orally to participants with advanced solid tumors, including rearranged during transfection (RET)-fusion-positive solid tumors, medullary thyroid cancer (MTC) and other tumors with RET activation

systemic therapy
ret inhibitor
cfdna
kidney function test
renal function
  • 1279 views
  • 22 Oct, 2022
  • 86 locations
Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158)

In this study, participants with multiple types of advanced (unresectable and/or metastatic) solid tumors who have progressed on standard of care therapy will be treated with pembrolizumab (MK

small intestine
small cell carcinoma
endometrial carcinoma
solid tumor
pembrolizumab
  • 15 views
  • 04 Oct, 2022
  • 24 locations
Study to Evaluate IMP9064 as a Monotherapy or in Combination in Patients With Advanced Solid Tumors

This is a Phase 1/2, multicenter, open-label study to evaluate the safety and efficacy of IMP9064 as monotherapy or in combination with PARP inhibitor Senaparib in patients with advanced solid

  • 0 views
  • 04 Oct, 2022
  • 8 locations